Genmab A/S (NASDAQ:GMAB) Shares Gap Up – What’s Next?

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) gapped up before the market opened on Tuesday . The stock had previously closed at $28.01, but opened at $29.02. Genmab A/S shares last traded at $28.8810, with a volume of 263,490 shares.

Analyst Ratings Changes

GMAB has been the topic of several research analyst reports. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Truist Financial initiated coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. HC Wainwright increased their price target on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Finally, Weiss Ratings lowered Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.21.

Genmab A/S Stock Performance

The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $18.06 billion, a PE ratio of 21.95, a PEG ratio of 1.83 and a beta of 0.84. The company has a 50-day moving average price of $26.20 and a two-hundred day moving average price of $28.65.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of GMAB. Personal CFO Solutions LLC lifted its holdings in shares of Genmab A/S by 3.7% in the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock worth $292,000 after buying an additional 386 shares in the last quarter. Founders Capital Management lifted its stake in Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Parallel Advisors LLC lifted its stake in Genmab A/S by 11.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares in the last quarter. CWM LLC boosted its holdings in Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after purchasing an additional 433 shares during the period. Finally, Osaic Holdings Inc. grew its position in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.